UK market entry, subsidiaries, Companies House, MHRA, medical devices, medicines, digital health, CETA, FEMA/ODI, VAT and regulatory readiness for Indian businesses

Updated: 29 August 2026

India is already one of the world’s major pharmaceutical, biotechnology and medical-technology centers.

For Indian manufacturers, pharmaceutical companies, MedTech businesses, diagnostics companies, HealthTech founders and life sciences organisations, the United Kingdom can represent an attractive international market.

But entering Britain successfully involves considerably more than registering a UK Limited Company.

An Indian business may be able to establish a UK subsidiary relatively easily from a corporate-law perspective. What happens next depends entirely on what the business actually intends to do in Britain.

Selling prescription medicines is not the same as distributing medical devices.

A diagnostic platform may fall within medical-device regulation.

A healthcare software business may or may not constitute Software as a Medical Device.

A company operating a healthcare service in England may face Care Quality Commission requirements.

A pharmaceutical manufacturer importing medicines from India may need regulatory authorizations that a software company would never encounter.

Therefore, the right starting question is not:

“Can an Indian pharmaceutical company register a UK company?”

Generally, it can.

The more important question is:

“What role will the UK company perform, and which regulatory permissions must exist before it can legally perform that role?”

This guide explains how to answer that question.

Quick Answer: Can an Indian Pharma or MedTech Business Set Up a UK Company?

Yes, generally.

An Indian founder can establish a UK Limited Company, and an existing Indian company can potentially establish a UK subsidiary, subject to the applicable corporate, Indian overseas-investment, tax and regulatory requirements.

A UK-resident director is not generally required for an ordinary private company limited by shares.

However, the company must have an appropriate UK Registered Office.

For new companies in 2026, Companies House identity-verification requirements must also be addressed. New directors are required to provide their Companies House personal code as part of the registration filing, and PSCs have separate verification requirements applicable to their role.

The current standard online Companies House incorporation fee is £100, with standard applications normally processed within around 24 hours, although complex applications may take longer.

But incorporation does not itself authorize the company to sell medicines, place medical devices on the UK market, provide regulated healthcare or conduct regulated clinical research.

That distinction is fundamental.

Start My UK Life Sciences Company

India → UK Life Sciences Decision Matrix

Key takeaway

For life sciences businesses, the regulatory role should help determine the corporate structure — not the other way around.

1. Why the UK Matters for Indian Life Sciences Businesses in 2026

The India–UK commercial corridor is becoming materially stronger.

Grant Thornton’s 2026 India Meets Britain research identifies 1,912 Indian-owned companies operating in the UK, generating more than £105 billion in combined turnover, with manufacturing and pharmaceuticals among the expanding sectors.

Life sciences also remain a strategic UK industry. The UK government’s 2026 Life Sciences Sector Plan includes investment in manufacturing, faster regulation, improved MHRA–NICE coordination, medical-device reform and measures intended to improve routes into NHS procurement.

For Indian companies, another major development occurred on 15 July 2026, when the UK–India Comprehensive Economic and Trade Agreement entered into force.

The opportunity is therefore real.

But market opportunity and regulatory permission remain separate matters.

2. UK–India CETA: Why It Matters for Pharma and MedTech

The UK–India Comprehensive Economic and Trade Agreement creates a significantly stronger framework for bilateral trade.

Indian government materials state that 56 pharmaceutical tariff lines receive zero-duty market access under the agreement, while several categories of medical devices — including certain surgical instruments, diagnostic equipment, ECG machines and X-ray systems — also benefit from duty-free access. 

The agreement also establishes rules governing product origin. Preferential tariffs are not available merely because goods are shipped from India: the product must satisfy the applicable CETA rules of origin and documentation requirements.

CETA also includes commitments relating to technical barriers to trade and promotes greater use of international standards while preserving product-safety requirements.

Its intellectual-property chapter covers patents, trade marks, designs, trade secrets and other IP rights.

What CETA does not mean

CETA does not mean:

Indian approval

automatic UK regulatory approval

Tariff access and product authorization are different systems.

An Indian medicine may still require the appropriate MHRA route.

An Indian medical device may still need the applicable conformity, UK Responsible Person and MHRA registration arrangements.

3. First Decision: What Exactly Is Your Product or Service?

Before forming the UK entity, identify the regulatory category.

This is especially important in life sciences because companies often describe themselves broadly as:

• healthcare;
• pharma;
• biotech;
• medical technology;
• digital health.

Regulators do not operate on marketing terminology.

They look at the actual product, intended purpose and activity.

The business may fall principally into one of the following categories.

A. Medicines

Prescription medicines, generic medicines, OTC medicinal products, biologics and other medicinal products.

B. Medical Devices

Examples may include diagnostic equipment, surgical devices, monitoring products and certain healthcare technologies.

C. In Vitro Diagnostics

Certain tests, analyzers and diagnostic products.

D. Software / AI as a Medical Device

Some clinical software and AI systems can themselves fall within the medical-device framework. MHRA specifically recognizes that software and AI may be regulated as medical devices or IVDs.

E. Healthcare Services

Companies actually providing regulated health or social-care activities in England can enter an entirely different regulatory framework involving the CQC.

F. Research / Clinical Trials

Biotech, pharmaceutical and research companies sponsoring UK clinical trials face separate requirements.

The correct classification should come before the regulatory and corporate roadmap.

4. Founder-Owned UK Ltd or Indian-Parent UK Subsidiary?

This is one of the most important structural decisions.

Option 1 — Founder-Owned UK Limited Company

Example:

Indian founder
↓
UK Ltd

This may be relevant where:

• the UK project is genuinely new;
• it is separate from an existing Indian company;
• the IP, contracts and operations are intended to belong to the new UK entity.

However, if the founder already operates a significant Indian pharmaceutical or MedTech business, separating the UK operation personally from the Indian company may create questions around:

• intellectual property;
• product ownership;
• licences;
• supply agreements;
• related-party transactions;
• transfer pricing;
• control.

It should therefore have a genuine commercial explanation.

Option 2 — Indian Parent → UK Subsidiary

Example:

Indian Pvt Ltd / Indian pharmaceutical company
↓
100% or controlled UK subsidiary
↓
UK market operations

For an established Indian manufacturer or healthcare group, this may be the more natural structure.

The UK company can potentially become the British operating arm while the Indian parent continues manufacturing, R&D or other operations in India.

Indian overseas investment rules must still be considered.

The Reserve Bank of India’s overseas-investment framework permits eligible Indian entities to make Overseas Direct Investment subject to the applicable Overseas Investment Rules, Regulations, reporting requirements and financial-commitment conditions.

For the specialist India-side rules, use Seven Oak Prestige’s:

FEMA & RBI Rules for UK Companies Owned by Indian Founders

Option 3 — No UK Company Initially

Sometimes the correct answer is no UK subsidiary yet.

An Indian manufacturer may initially enter Britain using:

• an independent distributor;
• authorized commercial partners;
• a UK Responsible Person where required for devices;
• contractual market-access arrangements.

Whether this is appropriate depends on who:

• imports;
• owns the product;
• holds regulatory authorizations;
• distributes;
• invoices customers;
• carries product liability.

A UK company should therefore solve a real commercial or regulatory problem.

5. Companies House Formation Requirements

Once the structure is decided, ordinary UK corporate requirements apply.

A private company will normally need:

• company name;
• at least one eligible natural-person director;
• shareholder information;
• PSC information;
• share structure;
• appropriate Registered Office;
• registered email address;
• SIC code;
• identity verification for relevant individuals.

Companies House currently charges £100 for standard online incorporation.

For Indian residents, see the broader formation guide:

How to Start & Register a UK Company from India — 2026 Guide

6. Companies House Identity Verification

Corporate formation changed materially after 18 November 2025.

New directors must now verify their identity and provide their Companies House personal code in connection with incorporation or appointment.

The code is an 11-character personal identifier and belongs to the individual rather than to one specific company. The same verified person can reuse that personal code for relevant roles across different companies. 

PSCs also have separate obligations for connecting their verified identity to their role.

For Indian founders:

Companies House Identity Verification for Indian Residents⁠

7. Choosing the Correct SIC Code

Life sciences businesses should avoid choosing a generic SIC code without analyzing the genuine activity.

Potential classifications depend on whether the UK company will perform activities such as:

• pharmaceutical manufacturing;
• pharmaceutical wholesale;
• research and development;
• medical-device distribution;
• software development;
• healthcare services.

The SIC code does not itself grant regulatory permission.

For example:

Selecting a pharmaceutical manufacturing SIC code does not create an MHRA manufacturing licence.

Similarly:

Registering a healthcare company at Companies House does not create CQC authorization.

Companies House registration identifies the company.

Sector regulators determine whether regulated activities may actually be conducted.

8. Medicines: Incorporation Is Only the First Layer

For Indian pharmaceutical businesses, the biggest mistake would be treating a UK subsidiary as though it were automatically authorized to commercialise medicines.

It is not.

Depending on what the company intends to do, different requirements can arise.

9. UK Marketing Authorization for Medicines

A medicinal product generally needs the appropriate Marketing Authorization before being placed on the UK market through the relevant route.

MHRA states that UK marketing-authorization applications are submitted through its Submissions Portal and must follow the applicable regulatory pathway and documentation requirements.

The regulatory basis depends on the product.

Established generics do not necessarily follow the same pathway as:

• new active substances;
• biologics;
• biosimilars;
• innovative products.

Therefore, “Indian pharma company” is not sufficient information to determine the regulatory route.

10. Where Can the Marketing Authorization Holder Be Established?

This point is particularly relevant to international businesses.

MHRA guidance states that a UK Marketing Authorization Holder must generally be established in the UK or EU/EEA, subject to the specific arrangements applicable to the authorization.

This means that establishing a substantive UK subsidiary can potentially form one component of an Indian pharmaceutical group’s regulatory architecture.

But a Companies House registration alone does not make the company operationally ready to act as a Marketing Authorization Holder.

Pharmacovigilance, responsible personnel, systems, documentation and applicable regulatory obligations must also be addressed.

11. Importing Medicines from India into Britain

If the business will physically move medicines from India into Britain, importation becomes a separate regulatory question.

MHRA distinguishes between several scenarios depending on:

• product authorization;
• source country;
• intended UK use;
• manufacturing/import arrangements.

For certain imports from countries outside the relevant approved-country framework, a manufacturing/import licence may be required. Wholesale activities can separately require a Wholesale Dealer’s Authorization.

This is why an Indian manufacturer should map:

Indian manufacturer
↓
exporter
↓
UK importer
↓
regulatory licence holder
↓
warehouse / wholesaler
↓
customer / NHS / pharmacy / private market

before shipping commercial stock.

12. Manufacturer and Wholesale Licences

MHRA states that businesses manufacturing, assembling or importing human medicines may require a manufacturer licence.

Businesses selling or supplying medicines wholesale may require a Wholesale Distribution Authorization — WDA(H) and must comply with Good Distribution Practice requirements. 

Therefore:

UK Ltd
≠
manufacturer licence

and:

UK Ltd
≠
wholesale dealer licence

The corporate entity creates the legal vehicle.

MHRA authorization determines what that vehicle is permitted to do within the regulated medicines supply chain.

13. Medical Devices: A Different Regulatory Framework

Indian medical-device companies should not apply pharmaceutical rules to devices.

Medical devices placed on the Great Britain market are regulated primarily through the UK medical-device framework administered by MHRA.

The framework addresses matters including:

• device classification;
• conformity;
• registration;
• UKCA;
• continuing recognition of qualifying CE-marked devices;
• UK Responsible Persons;
• post-market surveillance.

The exact requirements depend on the device.

14. UK Responsible Person for Indian Manufacturers

This is one of the most important distinctions for Indian MedTech companies.

MHRA states that a medical-device manufacturer based outside the UK must appoint a UK Responsible Person when placing devices on the Great Britain market. 

Therefore, an Indian medical-device manufacturer does not automatically need to create its own UK subsidiary merely because it needs a UK Responsible Person.

A qualifying third-party UKRP arrangement may be possible.

But an Indian business may still choose a UK subsidiary for commercial reasons such as:

• direct UK sales;
• employees;
• contracting;
• warehousing;
• local distribution;
• NHS procurement;
• investor presence;
• broader UK operations.

This is exactly why regulatory structure and corporate structure should be analyzed separately.

15. CE Marking and UKCA in 2026

The UK continues to operate transitional recognition arrangements for certain CE-marked medical devices in Great Britain while developing its future medical-device framework.

The precise recognition period depends on device type and regulatory route, so businesses should check current MHRA guidance rather than relying on older articles stating that “UKCA is now mandatory for everything.”

For Indian manufacturers, the practical sequence should be:

classify product correctly
↓
identify conformity route
↓
determine CE/UKCA position
↓
appoint UKRP if required
↓
register appropriately with MHRA
↓
establish importer/distributor chain
↓
enter market

not simply:

form UK Ltd
↓
sell device

16. Digital Health, Software and AI

This deserves special attention because India has a rapidly developing HealthTech and AI ecosystem.

Not every healthcare software product is a medical device.

But some are.

MHRA explicitly recognizes that software and artificial intelligence can qualify as Software as a Medical Device — SaMD or AI as a Medical Device depending on intended purpose and function. 

For example, there can be a major regulatory difference between:

appointment-management software

and software that:

analyses clinical information to diagnose or influence treatment decisions.

Indian HealthTech founders should therefore establish classification before assuming that a normal SaaS structure is sufficient.

For broader technology-company structuring:

UK Company for Indian SaaS, AI & Technology Founders⁠

17. Clinical Trials and Research Businesses

Indian biotech, CRO and pharmaceutical companies conducting clinical trials in Britain enter another regulatory layer.

The UK’s amended Clinical Trials Regulations took full effect on 28 April 2026.

Clinical-trial sponsors and investigators must comply with the applicable regulatory responsibilities.

Whether the sponsor must be established in an eligible jurisdiction, whether a representative is required, and what documentation must be submitted depends on the specific trial and regulatory framework.

A UK company may therefore play an important role in an international research structure, but its function should be designed around the clinical and regulatory model.

18. Providing Healthcare Services in England: CQC

Selling a pharmaceutical product is different from providing healthcare.

If an Indian healthcare group intends to establish:

• a clinic;
• diagnostic service;
• treatment service;
• certain remote healthcare services;
• other regulated care activities

in England, Care Quality Commission requirements must be considered.

CQC states clearly that organisations carrying on regulated activities in England must register, and providing a regulated activity without required registration is an offence.

Companies House incorporation does not replace CQC registration.

An Indian healthcare company should therefore determine:

what healthcare activity will be provided
↓
where it will be provided
↓
whether it is a regulated activity
↓
what CQC registration and registered-management structure is required

before treating the UK company as operational.

19. MHRA Approval Does Not Automatically Mean NHS Access

Another frequent international-market-entry mistake is treating regulatory approval and NHS commercial access as the same thing.

They are not.

The MHRA primarily addresses regulatory approval and safety.

NICE evaluates technologies and medicines in the context of clinical and cost effectiveness for relevant NHS pathways.

NHS procurement operates through its own commercial structures and frameworks.

The UK government’s 2026 Life Sciences Sector Plan itself distinguishes these layers and is working to improve coordination between MHRA, NICE and NHS market access.

NHS England also confirms that framework agreements are a common route through which NHS organisations purchase products and services.

Therefore:

MHRA approval
≠
NICE recommendation
≠
NHS procurement contract

A serious UK market-entry strategy should understand all three where applicable.

20. Indian Pharma and the NHS

For pharmaceutical businesses seeking NHS hospital access, commercial arrangements can include NHS medicines-procurement frameworks.

NHS England’s Medicines Procurement and Supply Chain function manages framework arrangements covering categories such as generics, branded medicines, biosimilars and certain specialist products.

For innovative products, NICE and NHS England may also become relevant to reimbursement and commercial access.

In 2026, MHRA and NICE introduced an Integrated Scientific Advice service designed to help developers align regulatory and health-technology-assessment considerations earlier in development.

This reinforces an important strategic point:

UK market entry should be designed backwards from the intended commercial destination, not forwards from Companies House incorporation.

21. VAT, EORI and Importation

Life sciences businesses moving goods into Britain should separately assess:

• importer of record;
• customs classification;
• applicable tariff treatment;
• CETA origin qualification;
• import VAT;
• UK VAT registration;
• EORI;
• warehousing;
• contractual ownership of inventory.

A UK subsidiary does not automatically solve those issues.

CETA may reduce tariffs where the relevant goods qualify, but preferential treatment still depends on product classification and origin rules.

For UK registrations:

UK VAT Registration Support⁠

UK EORI Registration Support⁠

22. Banking for Pharma, MedTech and Healthcare Companies

Companies House registration and banking approval remain separate decisions.

Life sciences companies can receive additional compliance questions because the activity may involve:

• regulated products;
• international manufacturers;
• multiple jurisdictions;
• high-value transactions;
• distributors;
• healthcare counterparties;
• IP and licensing;
• import/export flows.

A financial institution may therefore ask for:

• ownership chart;
• Indian parent details;
• Companies House documents;
• regulatory licences;
• website;
• product information;
• customer/supplier contracts;
• source of funds;
• expected transaction countries;
• explanation of the UK operation.

The strongest application is one where the regulatory and commercial story is already coherent.

For further preparation:

UK Business Bank Account for Indian Residents — 2026 Guide⁠

UK Business Banking Readiness Assessment⁠

23. UK Tax and Indian Tax

An Indian-owned UK subsidiary normally creates tax considerations in both jurisdictions.

Relevant topics can include:

• UK Corporation Tax;
• Indian tax treatment of overseas ownership;
• transfer pricing;
• related-party transactions;
• dividends;
• royalties;
• management charges;
• permanent establishment;
• place of effective management;
• UK–India treaty considerations.

This article should not reproduce the entire tax analysis.

The dedicated guide is:

UK Company Tax for Indian Residents: Corporation Tax, POEM & Double Taxation⁠

The key principle is simple:

The commercial, regulatory and tax structure should tell the same story.

24. Intellectual Property

For biotech, pharmaceutical, diagnostics and HealthTech companies, IP can be one of the most valuable assets in the entire business.

Before establishing a UK subsidiary, determine:

• who owns existing patents;
• who owns trademarks;
• who owns software;
• who develops new IP;
• whether the UK company receives ownership or merely a licence;
• how related companies compensate each other.

CETA contains commitments on intellectual-property protection, including patents, trade marks, trade secrets and enforcement.

However, the existence of treaty protection does not replace proper:

• IP assignments;
• licence agreements;
• intercompany contracts;
• transfer-pricing analysis.

25. India → UK Example Structures

Example A — Indian Generic Manufacturer

Indian pharmaceutical parent
↓
manufactures in India
↓
UK subsidiary
↓
regulatory / commercial role defined
↓
licensed UK supply chain
↓
private / NHS customers

Suitable where the UK company genuinely performs a British market function.

Example B — Indian MedTech Manufacturer

Indian manufacturer
↓
UK Responsible Person
↓
MHRA / conformity requirements
↓
UK importer/distributor
↓
UK market

A UK subsidiary may be added if direct commercial operations justify it.

Example C — Indian HealthTech Startup

Indian founders / Indian parent
↓
UK Ltd
↓
UK commercial contracts
↓
software classification review
↓
MHRA requirements if SaMD
↓
NHS/private healthcare opportunities

Example D — Indian Healthcare Group

Indian healthcare parent
↓
UK operating subsidiary
↓
staff / premises / service model
↓
CQC analysis and registration where required
↓
UK healthcare delivery

Each model begins with a different regulatory question.

26. Recommended India → UK Market-Entry Sequence

Step 1 — Define the UK commercial objective

Are you:

• exporting?
• distributing?
• selling directly?
• conducting R&D?
• providing healthcare?
• establishing an NHS presence?
• holding regulatory authorizations?

Step 2 — Classify the product or service

Medicine?

Device?

IVD?

Software?

AI?

Healthcare service?

Clinical research?

Step 3 — Map the UK regulatory pathway

Determine which regulators and licences may apply.

Step 4 — Choose the corporate structure

Compare:

Indian business only

vs

Founder-owned UK Ltd

vs

Indian parent → UK subsidiary

Step 5 — Review Indian ODI/FEMA implications

Especially where an existing Indian entity will own or fund the UK company.

Step 6 — Determine IP ownership

Before contracts and regulatory applications begin.

Step 7 — Complete Companies House preparation

Director, shareholder, PSC, SIC code, Registered Office and identity verification.

Step 8 — Incorporate

Only once the role of the UK entity is clear.

Step 9 — Complete regulatory work

Depending on activity:

MHRA / UKRP / MA / WDA(H) / manufacturer licensing / CQC / clinical research requirements.

Step 10 — Map importation and supply chain

Identify importer, distributor, inventory location, VAT and customs.

Step 11 — Build banking readiness

Prepare the corporate and regulatory evidence.

Step 12 — Develop the commercial route

Private market?

Distributor?

NHS?

Research partnership?

Licensing?

Step 13 — Establish ongoing compliance

Corporate, accounting, regulatory, tax and sector-specific.

27. Common Mistakes Indian Life Sciences Businesses Should Avoid

Creating the UK company before defining its role

A certificate of incorporation is not a market-entry strategy.

Assuming Companies House means MHRA approval

They perform different functions.

Assuming Indian regulatory approval automatically carries into Britain

It does not necessarily do so.

Assuming CETA removes regulatory requirements

CETA can improve trade conditions; it does not eliminate product regulation.

Creating a UK subsidiary when a distributor or UKRP arrangement would initially be sufficient

More structure is not automatically better.

Using a third-party distributor without clarifying importer and regulatory responsibilities

The supply chain must be explicit.

Confusing MHRA authorization with NHS market access

Regulatory approval and commercial procurement are separate.

Ignoring FEMA/ODI before the Indian parent funds the UK entity

The India-side investment structure matters.

Moving IP without proper agreements

Especially dangerous in biotech, pharma and software.

Treating a HealthTech platform as ordinary SaaS without checking medical-device classification

Intended clinical purpose can change the regulatory position.

Starting regulated healthcare activity without checking CQC requirements

For regulated activities in England, registration can be legally required.

28. Pre-Incorporation Checklist for Indian Pharma & MedTech Businesses

Corporate structure

• Indian parent or founder ownership decided
• UK subsidiary commercially justified
• Shareholding structure documented
• Director identified
• PSC identified
• FEMA / ODI reviewed
• IP ownership reviewed

Companies House

• Company name
• SIC code
• Registered Office
• Director Service Address
• Registered email
• Identity verification
• Companies House personal code

Regulatory

• Product/service classification
• MHRA pathway identified
• Marketing Authorization requirement checked
• Manufacturer/import licence requirement checked
• WDA(H) requirement checked
• UK Responsible Person requirement checked
• Medical-device registration/conformity reviewed
• CQC reviewed if healthcare services
• Clinical-trial requirements reviewed if applicable

Trade and operations

• CETA eligibility reviewed
• Rules of origin reviewed
• Importer of record identified
• EORI assessed
• VAT assessed
• Warehousing/distribution model established

Commercial readiness

• Banking documentation
• Regulatory evidence
• Website
• Product documentation
• Supply agreements
• Distributor agreements
• NHS/private-market route identified

FAQ — UK Companies for Indian Pharma, MedTech & Life Sciences Businesses

Can an Indian pharmaceutical company own a UK Limited Company?

Generally, yes. An Indian company can potentially own a UK subsidiary, subject to UK corporate requirements and applicable Indian overseas-investment rules.

Can an Indian founder personally own the UK company?

Potentially, yes. However, where an established Indian business already owns the products, IP and operations, personal ownership of a separate UK entity should have a clear commercial rationale.

Does the UK company need a UK-resident director?

A UK-resident director is not generally required for an ordinary private limited company.

Does the UK company need a UK address?

Yes. It requires an appropriate Registered Office in its jurisdiction of incorporation.

How much does Companies House incorporation cost?

The current standard online fee is £100.

Is Companies House identity verification required?

Yes, the mandatory framework now applies to new directors and relevant PSC roles. New directors need their personal code for registration.

Does registering a pharmaceutical UK Ltd allow it to sell medicines?

No. Corporate incorporation and medicines regulation are separate.

Does an Indian medicine automatically receive UK approval?

No. The appropriate MHRA regulatory pathway must be established.

Does a UK pharmaceutical importer need an MHRA licence?

Potentially. The required licence depends on the product, origin, authorization and activity.

What is WDA(H)?

It is the Wholesale Dealer’s Authorization used for regulated wholesale distribution of human medicines where applicable.

Does an Indian medical-device manufacturer need a UK company?

Not automatically.

A non-UK manufacturer placing a device on the Great Britain market generally needs a UK Responsible Person, but that does not itself mean the manufacturer must own a UK subsidiary.

What is a UK Responsible Person?

It is the UK-based person or entity appointed by an overseas medical-device manufacturer to perform specified regulatory responsibilities in relation to the Great Britain market.

Is CE marking still accepted in Britain?

Certain qualifying CE-marked medical devices continue to be recognised under transitional arrangements. The applicable position depends on device and regulatory route.

Can Indian HealthTech software fall under MHRA regulation?

Yes. Some software and AI products qualify as medical devices depending on their intended purpose.

Does a healthcare company need CQC registration?

If it carries on a regulated health or social-care activity in England, CQC registration can be legally required.

Does MHRA approval automatically provide access to the NHS?

No.

Regulatory approval, NICE assessment and NHS procurement are separate layers.

Does CETA mean Indian pharmaceutical products are automatically permitted in Britain?

No.

CETA can provide tariff and trade benefits for qualifying products, but regulatory requirements remain applicable.

Can CETA eliminate tariffs on Indian pharmaceutical products?

Certain pharmaceutical tariff lines receive zero-duty treatment, subject to the agreement’s tariff schedules and rules of origin.

Does an Indian parent need to consider FEMA/RBI rules before creating the subsidiary?

Yes. An Indian entity making overseas direct investment should review the applicable Indian ODI framework and reporting requirements.

Can a UK subsidiary open a business bank account?

Potentially, but approval is independent and subject to the financial provider’s KYC, AML, eligibility and risk assessment.

Does the UK company automatically need VAT?

No. VAT depends on the actual supplies and operational structure.

Does an Indian pharma exporter need an EORI?

Potentially, depending on its role in UK customs movements.

Can Seven Oak Prestige obtain MHRA approval for my pharmaceutical product?

Seven Oak Prestige’s corporate-formation and advisory support should be distinguished from specialist pharmaceutical regulatory representation. Where MHRA licensing, product authorization or specialist healthcare regulation is required, the appropriate regulated or specialist professionals should be engaged.

How Seven Oak Prestige Supports India → UK Life Sciences Expansion

Seven Oak Prestige supports Indian founders and businesses with the corporate and operational foundation required for UK expansion.

Support can include:

• UK Limited Company formation;
• Indian parent → UK subsidiary structuring;
• director and shareholder preparation;
• Companies House identity verification;
• Registered Office;
• Director Service Address;
• UK corporate compliance;
• VAT registration;
• EORI registration;
• banking and fintech readiness;
• KYC documentation preparation;
• post-incorporation coordination.

For sector-regulated activity, the corporate structure should be coordinated with the appropriate regulatory specialists.

Our role is not to suggest that:

“A UK Ltd gives an Indian pharmaceutical company access to the UK healthcare market.”

Our approach is:

Understand the product
↓
understand the commercial route
↓
choose the corporate structure
↓
complete Companies House
↓
identify regulatory permissions
↓
prepare the supply chain
↓
prepare banking and tax
↓
enter the UK market compliantly

Final Takeaway

For an Indian pharmaceutical, MedTech, biotech or HealthTech company, establishing a UK Limited Company can be strategically valuable.

But the company should have a clearly defined purpose.

For an established Indian manufacturer, an Indian-parent UK subsidiary may provide a coherent platform for British operations.

For a medical-device manufacturer using independent UK distribution, a separate UK subsidiary may not initially be necessary.

For HealthTech founders, the corporate structure must be considered alongside the possibility that software or AI falls within medical-device regulation.

For healthcare operators, Companies House incorporation may need to be followed by CQC registration before regulated services can begin.

For pharmaceutical companies, the corporate vehicle must fit into the wider MHRA, marketing-authorization, importation and distribution architecture.

And across all of these models, the new UK–India CETA creates additional commercial opportunity without eliminating the need for regulatory compliance.

The UK company is the legal platform. Regulatory approval, supply-chain design and commercial access determine whether that platform can actually operate.

Planning Your India → UK Life Sciences Expansion?

Start My UK Life Sciences Company

For Indian pharma, MedTech, biotech, diagnostics and HealthTech founders who have identified a genuine UK commercial opportunity.

Discuss My India → UK Pharma / MedTech Expansion

For established Indian manufacturers and healthcare businesses considering a UK subsidiary, market-entry structure or regulated British operation.

About the Author

Isaac Jackson

Founder & Editorial Director — Seven Oak Prestige Ltd

Isaac Jackson works with international entrepreneurs establishing and structuring UK companies for cross-border business.

Through Seven Oak Prestige, his work focuses on UK company formation for non-residents, Companies House compliance, corporate structuring, banking readiness and the practical requirements international founders face when building a credible UK business presence.

For Indian entrepreneurs, his editorial research covers the practical intersection between UK Limited Companies, Indian-owned businesses, Amazon and e-commerce operations, international exports, UK market entry, VAT, EORI, Companies House identity verification and banking preparation.

This guide was developed specifically for Indian Amazon sellers, e-commerce founders, manufacturers and exporters considering the United Kingdom as part of their international expansion strategy. Its purpose is not simply to explain how to register a UK company, but to help founders determine when a UK Ltd, a UK subsidiary or an existing Indian structure may be the more commercially appropriate route.

Editorial Approach

Seven Oak Prestige articles are written with a compliance-first and decision-focused approach.

Where a subject involves tax, customs, VAT, Indian FEMA/RBI rules, product regulation or other specialist legal considerations, the guide provides general strategic information and highlights when professional jurisdiction-specific advice may be required.

Author: Isaac Jackson
Founder & Editorial Director, Seven Oak Prestige Ltd
Specialist focus: UK Company Formation • International Founders • Cross-Border Business Structuring • E-commerce & Export Readiness • Companies House Compliance • Banking Readiness

Planning Your India → UK Expansion?

Whether you are an Amazon seller, D2C brand, manufacturer, exporter or established Indian company entering the British market, the right UK structure should follow your actual commercial model.

Seven Oak Prestige can assist with:

UK Company Formation • UK Subsidiary Structuring • Companies House Identity Verification • Registered Office • Director Service Address • VAT Registration • EORI Registration • Banking & Fintech Readiness • Post-Incorporation Compliance

Speak with Seven Oak Prestige

WhatsApp — Immediate Support
+44 7447 488755

Email
contact@sevenoakprestige.com

UK Office
+44 20 4578 0726

Seven Oak Prestige Ltd
UK Corporate Advisory for International Entrepreneurs

Seven Oak Prestige Ltd
UK Corporate Advisory for International Entrepreneurs

Related India Guides

Continue with the specialist guide relevant to your structure:

UK Company Formation from India — Complete 2026 Guide⁠

FEMA & RBI Rules for Indian Founders with UK Companies⁠

UK Company Tax for Indian Residents — POEM & Double Taxation⁠

Companies House Identity Verification for Indian Residents⁠

UK Business Bank Account for Indian Residents⁠

UK Company for Indian SaaS, AI & Technology Founders⁠

UK Company for Indian Amazon, E-commerce & Exporters⁠